Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • Tuesday
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHGlobeNewsWire • Tuesday
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding FranchiseSeeking Alpha • 10/20/26
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026GlobeNewsWire • 10/20/26
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/15/26
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsGlobeNewsWire • 10/06/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?The Motley Fool • 09/10/26
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/02/26
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take OffThe Motley Fool • 08/25/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeeking Alpha • 08/11/26
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/06/26
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y GrowthZacks Investment Research • 07/31/26
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 07/30/26
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026GlobeNewsWire • 07/16/26
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioGlobeNewsWire • 07/13/26
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHPRNewsWire • 07/02/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26